SMC announces October recommendations
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC) has declined to recommendJerini's hereditary angioedema (HAE) injection Firazyr (icatibant 30mg/3ml) for use in Scotland's NHS, as Jerini did not present a sufficiently robust economic case for acceptance.